AI Summary

Wistar scientists have developed a new type of bispecific T cell engager, or BTE, that is effective against ovarian cancer in preclinical studies. It's a major development for this type of immunotherapy, which has been used successfully against blood cancers but has so far been less effective in solid tumors.

AI summaries can be wrong sometimes—always verify important details using the source article.